- Home
- SPGI vs NVO Comparison
SPGI vs NVO Comparison
Compare SPGI & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPGI | NVO |
|---|---|---|
| Founded | 1860 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5B | 166.1B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | SPGI | NVO |
|---|---|---|
| Price | $431.33 | $40.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 11 |
| Target Price | ★ $562.67 | $51.00 |
| AVG Volume (30 Days) | 1.8M | ★ 13.8M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 0.91% | ★ 3.27% |
| EPS Growth | ★ 18.70 | N/A |
| EPS | ★ 14.66 | N/A |
| Revenue | ★ $6,063,000,000.00 | N/A |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $7.38 | $3.88 |
| P/E Ratio | $29.04 | ★ $13.60 |
| Revenue Growth | ★ 7.10 | N/A |
| 52 Week Low | $381.61 | $35.12 |
| 52 Week High | $579.05 | $81.44 |
Technical Indicators
Market Signals| Indicator | SPGI | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 62.04 |
| Support Level | $401.95 | $35.49 |
| Resistance Level | $446.83 | $50.30 |
| Average True Range (ATR) | 10.75 | 1.00 |
| MACD | 1.78 | 0.76 |
| Stochastic Oscillator | 74.01 | 98.70 |
Price Performance
Historical ComparisonAbout SPGI S&P Global Inc.
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.